• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    WDSrx Expands Warehouse Network

    Piramal Inks Clinical Supply Deal with Theratechnologies

    Recipharm Signs Manufacturing Deal with Enzymatica

    CDMO Northway Biotech Expands in U.S.

    Global Biosciences Co. Selects ValGenesis VLMS
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    WDSrx Expands Warehouse Network

    Piramal Inks Clinical Supply Deal with Theratechnologies

    Recipharm Signs Manufacturing Deal with Enzymatica

    CDMO Northway Biotech Expands in U.S.

    Lonza to Exit Pharma Softgels and Liquid-Filled Hard Capsules
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    WDSrx Expands Warehouse Network

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Improving Product Profitability

    CDMO Northway Biotech Expands in U.S.

    Global Biosciences Co. Selects ValGenesis VLMS

    Nexelis Acquires GSK Vax Lab in Marburg

    The Future of Clinical Trials Series: Part I
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

    CDMO Cognate BioServices Teams Up with L7 Informatics
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Flow Sciences

    Baxter BioPharma Solutions

    Emergent BioSolutions

    Aphena Pharma Solutions

    Adare Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Aphena Pharma Solutions

    Flow Sciences

    Baxter BioPharma Solutions

    PCI Pharma Services

    Emergent BioSolutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    The U.S. Biosimilars Market: Shaking the “Laggard” Label

    Biosimilar uptake set to reshape the U.S. market

    The U.S. Biosimilars Market: Shaking the “Laggard” Label
    The U.S. Biosimilars Market: Shaking the “Laggard” Label
    Figure 1: US biosimilar approvals, 2015-2019 Source: https://purplebooksearch.fda.gov/advanced-search
    The U.S. Biosimilars Market: Shaking the “Laggard” Label
    Figure 2: Marketing Authorization Status of FDA-Approved MAB Biosimilars Source: https://www.fda.gov/drugs/biosimilars/biosimilar-product-information
    Katya Svoboda and Bob Swann, ICON05.05.20
    Biosimilar uptake in the US market has, until now, stood in stark contrast to that in the EU, which has led the way in biosimilar approvals and use since 2006. There are many signs, however, that the US is on the cusp of a major shift with respect to biosimilars: competitive pricing pressure, regulatory changes, payer policies, resolution of litigation issues and growing comfort with biosimilars will finally converge to drive strong adoption.

    It is important for manufacturers—both of originator products and of biosimilars—to understand the drivers behind, and barriers to, acceptance and use of biosimilars so that they can adopt appropriate commercial strategies. Without the benefit of a crystal ball, it is still possible to speculate as to how biosimilars will reshape the US market, considering the EU’s experience and the context of US market dynamics.

    Playing Catch Up
    To date, the European Medicines Agency (EMA) has authorized 63 biosimilars (nine of which were since withdrawn from the market) while the US Food and Drug Administration (FDA) has approved only 26. The number of approvals is trending upward in the US, however, as seen in Figure 1. Six new biosimilars have been introduced to market between November 2019 and mid-March, 2020: (Zirabev (bevacizumab), Ruxience (rituximab), Trazimera (trastuzumab), Ogivri (trastuzumab), Truxima (rituximab), and Ziextenzo (pegfilgrastim).


    Figure 1: US biosimilar approvals, 2015-2019 Source: https://purplebooksearch.fda.gov/advanced-search

    Notably, regulatory approvals in the US are not always followed immediately by market launches due to various patent defenses and legal wrangling, which has not delayed launches to such an extent in the EU due to the different patent landscape. Of the 26 biosimilars approved, just over half (14) have actually launched. The delayed products include biosimilars for the blockbuster monoclonal antibodies (MABs) Remicade, Enbrel, Humira, and Herceptin.1

    The US pipeline of biosimilars is strong. According to GlobalData, seven biosimilars are in the pre-registration phase: one for Avastin (bevacizumab), two for Neupogen (filgrastim), three for Neulasta (pegfilgrastim), two for Lucentis (ranibizumab), and two for Rituxan (rituximab). Thus, many industry watchers have suggested that the US is at a tipping point in terms of biosimilar availability.

    Yet, just as approval does not equate to availability, availability does not equate to uptake at the levels seen in the EU. The biosimilar for Janssen Biotech’s Remicade, Pfizer’s Inflectra, which was approved in 2016, only garnered seven percent of the volume share of the market two years after its US launch while, Remicade’s US revenues fell by 24 percent. By contrast, in the EU, in the two years following competition from biosimilars, Remicade’s revenues were halved, and its biosimilars captured the majority of the market volume within months.2 

    A Root Cause Analysis
    There are fundamental differences in both the regulatory processes and the market dynamics of the US and the EU that account for much of the discrepancy in the uptake of biosimilars. Chief among these is the difference in the patent landscape, with some EU patents ending earlier and some originator companies generating more patent barriers in the US. The EU is thus several years ahead of the US with many blockbuster biologics reaching the market sooner and subject to competition from multiple biosimilars, resulting in falling prices and high biosimilar uptake.

    Another huge hurdle in the US market is the FDA requirement that biosimilars prove “interchangeability” with the originator before pharmacy-level substitution is permitted. To prove interchangeability, biosimilar manufacturers must conduct multiple-switch trials to demonstrate that switching between the reference product and the biosimilar poses no greater risk than using the reference product.3  

    Due to safety concerns around factors such as immunogenicity, biosimilars without proven interchangeability are usually reserved for treatment-naïve patients. To date, no marketed product has been subject to switching studies, and so none is considered interchangeable. Any biosimilar product with an interchangeable designation would enjoy a competitive advantage because 1) it confers one year of market exclusivity and 2) clinicians would be more comfortable switching to biosimilars for patients who have been stable on the originator product—patients who represent two-thirds of the commercial opportunity for biosimilars.

    The EMA, on the other hand, does not have a specific “interchangeable” designation for biosimilars and has deferred all decisions on interchangeability, switching, and substitution to member states. Several EU countries—The Netherlands, Finland, Germany, UK, and Italy—have allowed biosimilars to be interchanged for biologics, with certain provisions. Automatic substitution at the pharmacy is not permitted in most EU countries.4

    Another significant difference is the fragmentation of the US market – compared with EU single-payer healthcare systems – and the resulting differences in acquisition practices and pricing.

    In the US, the key factor affecting biosimilar uptake is payers’ perception of safety and efficacy, as well as their management practices, which are driven by pricing and manufacturer rebates. Early-entrant biosimilars have difficulty competing against the contracting and rebating power of the originator manufacturers.

    In contrast, in the EU, biologics are often procured through tenders, and biosimilars often win by offering the lowest prices. Uptake is generally higher in markets that conduct national tenders using an exclusive approach—a practice that will become more common in time.

    Furthermore, EU payers are actively encouraging the uptake of biosimilars by setting quotas, providing guidance, and introducing incentives for physicians to prescribe biosimilars.

    A New Era in the US
    There are several drivers of biosimilar uptake, with lower acquisition cost being the primary one. Others include perceived quality, safety, clinical efficacy, manufacturing reliability, payer management, reimbursement rates set by Medicare and commercial payers, out-of-pocket expenses for patients, and education of physicians and patients. Going forward, some of these “dials” will be turned, and the conditions under which biosimilars launch will be different than in the past. Let’s review what changes are afoot and how they may impact the market performance of biosimilars:

    Introduction of multiple competitive products
    In the short term, we can expect a blizzard of biosimilars to be introduced for the MAB blockbusters, Avastin, Herceptin, and Humira. It is clear, that although delayed by several years due to patent litigation issues, five biosimilars to Humira will hit the market in 2023, and this will be a key development to watch (see Figure 2).


    Figure 2: Marketing Authorization Status of FDA-Approved MAB Biosimilars  Source: https://www.fda.gov/drugs/biosimilars/biosimilar-product-information

    AbbVie’s Humira is one of the world’s top selling products, so when five biosimilars were introduced in the EU, it triggered a competitive frenzy. Humira’s sales declined sharply while in some countries, adalimumab prices plummeted up to 80 percent of Humira’s price.5

    This influx of multiple biosimilars for a single indication will exert downward pressure on pricing in a way that single competitors have not. Today in the US, biosimilars offer about a 20 percent discount over the price of the originator, which is insufficient to unseat originators, given their contracted discounts. Once there are three biosimilars or more for any given originator, the degree of competition will drive prices down for the biosimilars and the originator alike. While this is the case, the number of biosimilar competitors entering the market will be limited by significant barriers to entry such as high development and manufacturing costs and the need to provide commercial and marketing support biosimilar products once launched.

    Certainly, biosimilars won’t be discounted to the extent that small-molecular-weight generics are, where the barriers to entry are lower. But, how low, may they go? A big factor will be the sales volumes biosimilars achieve. In the EU, payers have been able to negotiate discounts as much as 80 percent of the originator prices. Only in a few instances and select areas have originators been able to maintain their market share by offering high rebates. This degree of discounting may not be replicated in the US, because of the fragmented payer environment, but the discounts will certainly be greater than they have been to date.

    Changes to “level the playing field”
    Under Medicare, clinicians are reimbursed for the biologics that they purchase and administer to their patients through the buy-and-bill model. Currently, that reimbursement rate is calculated for branded products based on the average sales price (ASP) of the product plus 6 percent (due to sequestration, this is currently 4.3 percent). For biosimilars, they are reimbursed based on the ASP of the biosimilar, plus 6 percent of the ASP of the originator product. The Grassley-Wyden bill, which has passed the Senate Finance Committee at this writing, would increase reimbursement for the biosimilar to ASP plus 8 percent for five years after the biosimilar’s launch. This would create financial incentives for physicians to start new patients on the biosimilar product.

    The Centers for Medicare and Medicaid Services (CMS) is proposing to allow Medicare Part D plans to add a second specialty formulary tier for “preferred, lower cost” products that could include biosimilars, starting in 2021. This would result in lower coinsurance obligations for patients, driving utilization.

    Private payers are also taking steps to institute utilization management policies to promote the use of biosimilars over originators for new patients. These tactics may include creating a biosimilar tier with a more favorable cost structure for patients (lower patient cost sharing), requiring additional justification and/or requirements for use of originator brands, such as instituting step therapy, and implementing differential reimbursement for physicians to drive biosimilar use. 

    States, which have authority over local substitution laws, have been enacting laws to govern when biosimilars can be substituted for reference products. In a majority of states, pharmacists are permitted or even required to dispense an interchangeable biosimilar in certain situations, although no products have interchangeable status as yet, so this is not happening.6 Most require that the biosimilar be designated as interchangeable and that the switch be confirmed by the physician.

    Patent defense limitations
    Several originator companies have successfully erected legal barriers to prevent or delay biosimilars from launching. AbbVie, for instance, has controlled the timetable for five competitive launches to Humira—delaying them until 2023—as the biosimilar manufacturers agreed to settle and pay a license fee rather than launch “at risk” before the resolution of AbbVie’s patent infringement suits. Eventually, these strategies will run out of runway, and biosimilars will enter an altered market. In Humira’s case, the other factors discussed here will likely contribute to very rapid uptake when biosimilars launch in 2023.

    Increased education
    Clearly, for biosimilars to gain wider acceptance, education needs to be part of the solution. Patients typically take the advice of their physicians on the safety and efficacy of biosimilars, but clinicians have shown some reservations around biosimilars. 

    Since 2015, the FDA has acknowledged its role in educating healthcare professionals and patients with trustworthy, unbiased information on biosimilars. The agency’s 2018 Strategic Policy Roadmap included a comprehensive program to encourage biosimilar competition. The FDA has the advantage of being seen as neutral, but biosimilar manufacturers would also need to educate providers and patients through a variety of media, including speaker programs, educational materials, patient support programs and hub services.

    The Final Analysis
    There is every reason to believe that many of these conditions will occur, creating a “perfect storm” that will stimulate biosimilar adoption for treatment-naïve patients. And, any biosimilar that achieves the interchangeable designation would also attract existing patients.

    We can draw several lessons from the experience of biosimilars in the EU, coupled with our knowledge of US market dynamics. First, biosimilar discounts will be steeper and net prices lower than many expect.

    Second, while market dynamics are different in the US, payers will put in place processes that encourage physicians to prescribe biosimilars, and we believe biosimilars will succeed in capturing a significant share of the market. The market will, indeed, be dramatically different, and the US will at last realize the cost savings that biosimilars have promised. 

    References
    1. Harston, Aydin, “US Biosimilar Launches Accelerate with Five Launches in Q4 2019 and early 2020,” January 27, 2020. Accessed at https://www.biosimilarsip.com/2020/01/28/u-s-biosimilar-launches-accelerate-with-five-launches-in-q4-2019-and-early-2020/
    2. Wesley, Tim, “Biosimilars in the US and Europe: Biosimilar Insights,” Datamonitor Healthcare, June 25, 2019.
    3. https://www.fda.gov/drugs/biosimilars/biosimilar-and-interchangeable-products
    4. Ebbers, Hans C., Schellekens, “Are we ready to close the discussioin on the interchangeability of biosimilars?” Drug Discovery Today, Vol 24, Issue 10, October 2019, Pgs. 1963-1967.
    5. Wesley, Tim, “Biosimilars in the US and Europe: Biosimilar Insights,” Datamonitor Healthcare, June 25, 2019. 
    6. https://www.fda.gov/drugs/biosimilars/biosimilar-and-interchangeable-products
    7. https://www.mintz.com/insights-center/viewpoints/2801/2019-02-_5-states-now-have-biosimilar-substitution-laws


    Katya Svoboda and Bob Swann are Senior Principals in Global Pricing and Market Access at ICON. They deliver strategic market access solutions to define, capture and communicate the value of medical therapies for clients, to optimize commercial results and drive patient access. The authors also wish to thank Gene Chieh and Kristen Foote who contributed to this article. For more information visit www.ICONplc.com/access.
    Related Searches
    • Biosimilars

    Related Features

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20

    • Biosimilars
      Biosimilar Manufacturing Strategies

      Biosimilar Manufacturing Strategies

      Five steps to competing in a post-patent expiry era.
      George I’ons, Owen Mumford Pharmaceutical Services 09.09.20

    • Biologics, Proteins, Vaccines | Biosimilars
      Biopharma Over 20 Years

      Biopharma Over 20 Years

      A look at the key trends that have impacted the biopharma industry over the years.
      K. John Morrow, Jr. and Eric S. Langer, BioPlan Associates 11.20.19


    • Biologics, Proteins, Vaccines | Biosimilars
      Are Biotech Companies Strong Investments?

      Are Biotech Companies Strong Investments?

      Biotech capital raised via IPO has increased dramatically over the past couple of years.
      Jason Monteleone , CEO, Clinipace 05.07.19

    • Biosimilars
      Biosimilar  Market Trends

      Biosimilar Market Trends

      2017 was a record year for biosimilar approvals.
      Fiona Greer and Bruno Speder, SGS 09.11.18

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Haste Makes Waste

      Haste Makes Waste

      When to sprint and when to breathe in the race from lab to clinic.
      Christian Cattaruzza, MilliporeSigma 09.11.18


    • Biologics, Proteins, Vaccines | Biosimilars
      Biopharma Manufacturing Markets

      Biopharma Manufacturing Markets

      Biomanufacturing contract services and supplies markets continue to expand
      Ronald A. Rader and Eric S. Langer, BioPlan Associates 05.08.18

    • Biologics, Proteins, Vaccines | Biosimilars
      Contract BioManufacturing in China: Creating a New Segment

      Contract BioManufacturing in China: Creating a New Segment

      An up-close look at China’s growing market for CMO services.
      Vicky Qing Xia and Leo Cai Yang, BioPlan Associates 04.10.18

    • Biologics, Proteins, Vaccines | Biosimilars | cGMP Manufacture
      Biopharmaceutical Contract Manufacturing Market

      Biopharmaceutical Contract Manufacturing Market

      The market continues to grow, projected to exceed $4 billion in 2017
      William Downey, President, HighTech Business Decisions 06.06.17


    • Aseptic Processing | Biosimilars | Drug Delivery | Logistics | Supply Chain
      Improving Packaging Processes to Meet Regulatory and Patient Needs

      Improving Packaging Processes to Meet Regulatory and Patient Needs

      The rise of advanced automation and packaging technologies
      06.02.16

    • Biosimilars | Drug Delivery | Injectables | Parenterals | Serialization | Supply Chain | Vials
      Contract Packaging Market Trends

      Contract Packaging Market Trends

      Contract packagers talk about hot growth areas and the looming 2017 DSCSA deadline
      Tim Wright, Editor 06.02.16

    • Biosimilars | Chemistry | Process Development | Supply Chain
      Biopharma CMO Market Trends

      Biopharma CMO Market Trends

      Continued strong growth in biopharma industry is being driven by biosimilars
      Tim Wright, Editor 06.02.16


    • Biosimilars | Clinical Trials | Formulation Development
      Critical Steps for Biosimilar Assessment

      Critical Steps for Biosimilar Assessment

      Establishing “finger-print like” biosimilarity prior to the clinic
      Fiona Greer, SGS 05.05.16

    • Biosimilars | Clinical Trials | Drug Development
      The Evolving Landscape of Drug Development in China

      The Evolving Landscape of Drug Development in China

      Innovation agenda includes expanded use of biosimulation
      Christine Yuying Gao and Ellen Leinfuss, Certara 05.05.16

    • Biosimilars | Clinical Trials | Process Development
      Biosimilars Outsourcing and Capacity

      Biosimilars Outsourcing and Capacity

      CMOs to play important but uncertain role in biosimilars manufacturing
      Ronald A. Rader and Eric S. Langer, BioPlan Associates 05.05.16

    Trending
    • Lonza To Exit Pharma Softgels And Liquid-Filled Hard Capsules
    • The Future Of Clinical Trials Series: Part I
    • Grifols Begins COVID-19 Plasma Treatment Trial
    • Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    • NovaQuest Private Equity Acquires CoreRx
    Breaking News
    • WDSrx Expands Warehouse Network
    • Piramal Inks Clinical Supply Deal with Theratechnologies
    • Recipharm Signs Manufacturing Deal with Enzymatica
    • CDMO Northway Biotech Expands in U.S.
    • Global Biosciences Co. Selects ValGenesis VLMS
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    NIH Study Compares Low-Fat, Plant-based to Low-Carb, Animal-Based Diet
    Gadot Positions Mineral Line for Vegan Market
    Nutritfy India to Launch Global Broadcast Channel Covering Nutrition
    Coatings World

    Latest Breaking News From Coatings World

    IGL Coatings Launches Graphene Reinforced Dual System Ceramic Coating
    Miller Paint Declares Simple Serenity its 2021 Color of the Year
    TAUBMANS Paint by PPG Releases ‘Chromatic Joy’ Palettes
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    TPI Partners with Zeiss
    PPE Moves into New Manufacturing Facility
    Neurent Medical Closes $25 Million Series B Financing
    Contract Pharma

    Latest Breaking News From Contract Pharma

    WDSrx Expands Warehouse Network
    Piramal Inks Clinical Supply Deal with Theratechnologies
    Recipharm Signs Manufacturing Deal with Enzymatica
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Lageen Tubes Launches Mono-Material PE Tube Solutions
    Jason Jones Loses Battle with Covid-19
    Weleda Celebrates 100 Years By 'Opening' Its Gardens
    Happi

    Latest Breaking News From Happi

    NY's 1,4-Dioxane Law May Impact Concentrated Cleaners
    Sabinsa's Top Scientist Addresses US FDA
    Ipsy Adds New Personal Care Brand
    Ink World

    Latest Breaking News From Ink World

    Morancé Soudure France Adds Comexi F2 MC 10-color Flexo Press
    THIMM Group Installs 1st Koenig & Bauer CorruFLEX
    Cowan Graphics Adds Fujifilm Inca OnsetX3 HS
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Lemu Group engineers mask-making machine
    Niagara Label upgrades with Nilpeter flexo press
    Soma partners with Moore & Moore in US
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Lemu Group Engineers Mask-Making Machine
    Armbrust American Adds Meltblown Manufacturing
    P&G Reports 8% Sales Increase
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Siemens Healthineers’ DR Systems Cleared by FDA
    Former Medtronic Exec Appointed Zimmer Biomet's Chief Transformation Officer
    SeaSpine Launches Regatta Lateral Plates
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    UDC Subsidiary Adesis' Website Wins 2020 MarCom Platinum Award
    Roadsimple Modernizes Warehouse Ops with Zebra Technologies
    Graphene Flagship Launches Redesigned Website

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login